This transcript has been edited for clarity.
Today we will talk about the new automated results Insulin A delivery system that I think is really useful for many people Type 1 diabetes..
Dr. Steven Russell presented the results at the Diabetes Advanced Technology and Treatment (ATTD) Conference. This study focused on the iLet system, which was created and developed by Beta Bionics for some time. Since this was a monohormone study, I just looked at an algorithm that used only insulin.Eventually they will study this and consider using insulin plus. Glucagon Together we will see if it further improves the results.
One of the main reasons I think this study was so cool was that it included more than 25% of minority individuals who were not routinely studied in these insulin device trials.The study included a wide range of people A1c Level; There were no high cut points here. Over 30% of participants had more than 8% A1c. They also studied both children and adults and combined the results.
Before we talk about the results, let’s talk about pumps. It is a tube pump with a sensor to communicate (Dexcom sensor) and has an algorithm for automatic insulin delivery. Instead of entering all sorts of information into the system, this only requires you to put in the patient’s weight. that’s it. From there, the system begins to understand what the patient needs for automatic insulin delivery.
There are several target settings you can enter and may vary depending on the time of day. There are basically meal times, so there are breakfast, lunch, supper, and basically small, medium, and large meal sizes. Since the individual inputs this in real time, the system knows that it is eating, but otherwise the system works fine.
It does this in a way that does not allow the individual using the pump to tinker with it. They cannot disable the system and cannot enter other insulin doses. The system is just to take care of their diabetes.
They compared this system with people from other systems, including other automated insulin delivery systems, and included them in this trial. People were randomized to this system against what they were doing (it was a control group) and they followed them for 13 weeks, but it’s not that long.
A1c decreased by 0.5% between the two groups. Time within range also increased, and this improvement in time within range occurred almost immediately within a day or two of joining the system. In terms of actual numbers, adult patients started in the time range of 56%, which increased to 69% by the end of the study. The greatest improvement was in the overnight range, as seen with other automated insulin delivery systems.
When blood glucose was below 54, there was no time reduction and the number of severe episodes increased. Hypoglycemia In the group treated with the iLet system, this was not statistically significant between the two groups.
These results may be difficult to compare with other important trials investigating automated insulin delivery systems. The Tandem major clinical trials It was a randomized controlled trial similar to this, Medtronic When Omnipod The study was a single-arm study comparing patients before and after using the device.
Above all, I think the important thing about this system is that it may be possible to increase the use of automated insulin delivery systems. Devices that may allow primary care providers to use these systems without the need for any kind of support and require patients to count and adjust carbohydrates in a way that tends to be fairly complex. You may be able to use these devices more easily than you need higher computing and literacy.
I couldn’t be happier anymore. I like what they do at Beta Bionics and look forward to more results. In particular, see if these results are further improved when you do insulin research. Glucagon With their dual hormone pump system.
Thank you very much. This is Dr Anne Peters from Medscape.
Anne L. Peters, MD, is a professor of medicine at the University of Southern California (USC) Keck School of Medicine and director of the USC Clinical Diabetes Program. She has published more than 200 articles, reviews, summaries, and three books on diabetes and is a researcher in more than 40 research studies. She has spoken internationally in more than 400 programs and has joined many committees of several specialized organizations.
Follow us for news on diabetes and endocrinology twitter When Facebook
